Buy Stock In Gw Pharmaceuticals Apr 2026

GW Pharmaceuticals pioneered the use of cannabis-derived medicines, most notably . Since the acquisition, this platform has become a cornerstone of the Jazz Pharmaceuticals business model.

: By acquiring GW, Jazz Pharmaceuticals significantly reduced its reliance on its flagship narcolepsy drug, Xyrem . The combined company now has a robust portfolio across neuroscience and oncology. buy stock in gw pharmaceuticals

If you are looking to buy stock in , it is important to know that as of April 28, 2026, the company no longer trades under its own ticker symbol. It was fully acquired by Jazz Pharmaceuticals in May 2021 for approximately $7.2 billion. The combined company now has a robust portfolio

To invest in the GW Pharmaceuticals portfolio today, you would need to buy shares of its parent company, . To invest in the GW Pharmaceuticals portfolio today,

: Epidiolex was the first FDA-approved plant-derived cannabinoid medicine, used to treat severe forms of childhood-onset epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. It reached over $500 million in annual net sales in 2020 and has continued to expand globally as Epidyolex in Europe.

: The acquisition included GW’s cannabinoid product platform and clinical-stage programs for additional indications such as autism, schizophrenia, and multiple sclerosis-related spasticity.